1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Anti-obesity Drugs Market in the US 2015-2019

Anti-obesity Drugs Market in the US 2015-2019

  • July 2015
  • -
  • Infiniti Research Limited
  • -
  • 82 pages

About Obesity
Obesity is a complex multifactorial disorder characterized by the excessive accumulation and storage of fat in the body. In the recent years, this chronic illness is being considered as a global epidemic owing to its strikingly increasing incidence rates, especially in the in low and middle-income countries. Sedentary lifestyles and lack of physical activity coupled with consumption of high-calorie diet are considered to be the most preventable causes of obesity. Being either overweight or obese is considered as a risk factor for the development of multiple chronic diseases including cardiovascular disorders such as coronary heart disease, dyslipidemia, hypertension; metabolic disorders such as diabetes; and cancers to highlight a few. Although anti-obesity drugs are available in the market, their effectiveness is restricted to maintain weight rather than cure.

Technavio's analysts forecast the anti-obesity drugs market in the US to grow at a CAGR of 24.52% over the period 2014-2019.


Covered in this Report
The report covers the present scenario and the growth prospects of the anti-obesity drugs market in the US for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of the currently approved patented drugs, generics, OTC products, and the available generics that are used for the treatment of obesity.

Technavio's report, Anti-obesity Drugs Market in the US 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects in the coming years. The report includes a discussion of the
key vendors operating in this market.

Key Vendors
- Arena Pharmaceuticals
- F. Hoffmann-La Roche
- GlaxoSmithKline
- Novo Nordisk
- Orexigen Therapeutics
- Vivus

Other Prominent Vendors
- Alizyme
- Amylin
- Boehringer Ingelheim
- Eisai
- Merck
- Norgine
- Pfizer
- Rhythm Pharmaceuticals
- Shionogi USA
- Takeda Pharmaceutical
- Zafgan

Key Market Driver
- Growing Prevalence Population
- For a full, detailed list, view our report

Key Market Challenge
- Serious Adverse Events and Multiple Drug Withdrawals
- For a full, detailed list, view our report

Key Market Trend
- Diversification of Investigational Pipeline
- For a full, detailed list, view our report


Key Questions Answered in this Report
- What will the market size be in 2019 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

Table Of Contents

Anti-obesity Drugs Market in the US 2015-2019
01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
04. Product Profiles
04.1 Xenical
04.2 Qsymia
04.3 Belviq
04.4 Saxenda
04.5 Contrave
05. Market Research Methodology
05.1 Market Research Process
05.2 Research Methodology
06. Introduction
07. Disease Overview
07.1.1 Understanding the Disease
07.1.2 Etiology and Comorbidities
07.1.3 Classification of Obesity
07.1.4 Epidemiology
07.1.5 Economic Burden Due to Obesity
08. Market Landscape
08.1 Market Overview
08.2 Market Size and Forecast
08.3 Five Forces Analysis
09. Market Segmentation by Drug Class
09.1 Peripherally Acting Anti-obesity Drugs
09.2 Centrally Acting Anti-obesity Drugs
10. Market Segmentation by Medication Type
10.1 Monotherapies
10.2 Polytherapies
11. Buying Criteria
12. Market Growth Drivers
13. Drivers and Their Impact
14. Market Challenges
15. Impact of Drivers and Challenges
16. Market Trends
17. Trends and Their Impact
18. Vendor Landscape
18.1 Competitive Scenario
18.1.1 Key News
18.1.2 Mergers and Acquisitions
18.2 Market Share Analysis 2014
18.2.1 F. Hoffmann-La Roche
18.2.2 GlaxoSmithKline
18.2.3 Vivus
18.2.4 Arena Pharmaceuticals
18.2.5 Orexigen Therapeutics
18.2.6 Novo Nordisk
18.3 Other Prominent Vendors
19. Key Vendor Analysis
19.1 Arena Pharmaceuticals
19.1.1 Key Facts
19.1.2 Business Overview
19.1.3 Geographical Segmentation
19.1.4 Business Strategy
19.1.5 Recent Developments
19.1.6 SWOT Analysis
19.2 F. Hoffmann-La Roche
19.2.1 Key Facts
19.2.2 Business Overview
19.2.3 Business Segmentation
19.2.4 Business Segmentation by Revenue 2012 and 2013
19.2.5 Geographical Segmentation by Revenue
19.2.6 Business Strategy
19.2.7 Key Information
19.2.8 SWOT Analysis
19.3 GlaxoSmithKline
19.3.1 Key Facts
19.3.2 Business Overview
19.3.3 Business Segmentation
19.3.4 Business Segmentation by Revenue 2012 and 2013
19.3.5 Sales by Geography
19.3.6 Pipeline Products
19.3.7 Business Strategy
19.3.8 Key Information
19.3.9 SWOT Analysis
19.4 Orexigen Therapeutics
19.4.1 Key Facts
19.4.2 Business Overview
19.4.3 Business Strategy
19.4.4 Recent Developments
19.4.5 SWOT Analysis
19.5 Vivus
19.5.1 Key Facts
19.5.2 Business Overview
19.5.3 Business Segmentation by Revenue 2013
19.5.4 Business Segmentation by Revenue 2012 and 2013
19.5.5 Geographical Segmentation by Revenue 2013
19.5.6 Business Strategy
19.5.7 Recent Information
19.5.8 SWOT Analysis
19.6 Novo Nordisk
19.6.1 Key Facts
19.6.2 Business Overview
19.6.3 Business Segmentation by Revenue 2013
19.6.4 Business Segmentation by Revenue 2012 and 2013
19.6.5 Sales by Geography
19.6.6 Business Strategy
19.6.7 Key Information
19.6.8 SWOT Analysis
20. Other Reports in This Series


List of Exhibits
Exhibit 1: Market Research Methodology
Exhibit 2: Causes and Comorbidities of Obesity
Exhibit 3: Prevalence of Adults Overweight or Obese in US
Exhibit 4: Prevalence of Adults Overweight or Obese in US
Exhibit 5: Prevalence Rate of Children Overweight or Obese in US
Exhibit 6: Anti-obesity Drugs Market in US 2014-2019 ($ millions)
Exhibit 7: Segmentation of Anti-obesity Drugs Market in US by Drug Class
Exhibit 8: Segmentation of Anti-obesity Drugs Market in US by Medication Type
Exhibit 9: Pipeline Snapshot
Exhibit 10: Key Takeaways: F. Hoffman-La Roche
Exhibit 11: Key Takeaways: GlaxoSmithKline
Exhibit 12: Key Takeaways: Vivus
Exhibit 13: Key Takeaways: Arena Pharmaceuticals
Exhibit 14: Key Takeaways: Orexigen
Exhibit 15: Key Takeaways: Novo Nordisk
Exhibit 16: Arena Pharmaceuticals: Geographical Segmentation
Exhibit 17: F. Hoffmann-La Roche: Business Segmentation by Revenue 2013
Exhibit 18: F. Hoffmann-La Roche: Business Segmentation by Revenue 2012 and 2013
Exhibit 19: F. Hoffmann-La Roche: Revenue of Pharmaceuticals Division by Geography 2013
Exhibit 20: F. Hoffmann-La Roche: Revenue of Diagnostics Division by Geography 2013
Exhibit 21: GlaxoSmithKline: Business Segmentation 2013
Exhibit 22: GlaxoSmithKline: Business Segmentation by Revenue 2012 and 2013 ($ billions)
Exhibit 23: GlaxoSmithKline: Sales by Geography 2013
Exhibit 24: GlaxoSmithKline: Pipeline Products 2013
Exhibit 25: Vivus: Business Segmentation by Revenue 2013
Exhibit 26: Vivus: Business Segmentation by Revenue 2012 and 2013 ($ millions)
Exhibit 27: Vivus: Geographical Segmentation by Revenue 2013
Exhibit 28: Novo Nordisk: Business Segmentation by Revenue 2013
Exhibit 29: Novo Nordisk: Business Segmentation by Revenue 2012 and 2013 ($ billions)
Exhibit 30: Novo Nordisk: Sales by Geography 2013

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Obesity Treatment Market Size & Forecast, By Drugs, By Surgery & Devices And Trend Analysis To 2024

Obesity Treatment Market Size & Forecast, By Drugs, By Surgery & Devices And Trend Analysis To 2024

  • $ 4950
  • Industry report
  • September 2016
  • by Grand View Research

The global obesity treatment market is expected to reach USD 15.6 billion by 2024, according to a new report by Grand View Research, Inc. Upward trend in sedentary lifestyles, physical inactivity, and ...

Global Intragastric Balloons Market - Strategic Assessment and Forecast Till 2021

Global Intragastric Balloons Market - Strategic Assessment and Forecast Till 2021

  • $ 2995
  • Industry report
  • October 2016
  • by Beige Market Intelligence

The global intragastric balloons market is expected to grow at a CAGR of more than 7.01% till 2021. Global Intragastric Balloons Market - Strategic Assessment and Forecast till 2021 market research report ...

Obesity-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016

Obesity-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016

  • $ 2000
  • Industry report
  • November 2016
  • by Delve Insight

DelveInsight’s Report, “Obesity-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016”, provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline ...

Obesity-api Insights, 2016

November 2016 $ 1250

ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.